Technological integration in clinical practice has played a major role in reshaping oncological care over the past several years. Software systems have become essential tools for patient care management, chemotherapy protocol optimization, and treatment delivery standardization as cancer care becomes more data-driven. A number of companies have contributed to this rapidly expanding digital ecosystem, helping hospitals and clinics adopt more structured and efficient workflows. Altai Oncology, among them, represents a health technology company that has gradually expanded from a localized initiative into a globally recognized developer of oncology-focused medical software.
Altai Oncology was established in 2013 in the United States under the leadership of its founder and current chief executive, Ulas Darda Bayraktar. Operating initially as Altai LLC, the company began as a small health information technology venture dedicated to creating digital tools for oncologists and hematologists. Its first major product, the Altai Oncology Suite, was introduced as a Windows-based desktop application designed for cancer centers and infusion clinics. The software aimed to bring structure to chemotherapy management by offering modules for order entry, dose calculation, pharmacy coordination, scheduling, and registry reporting.
The early versions of the Oncology Suite quickly gained the attention of early adopters, especially oncologists seeking ways to make complex treatment workflows more efficient. The platform’s modular architecture enabled cancer clinics to record, calculate, and manage their data in real time, helping ensure that clinical decisions closely aligned with documented treatment plans. By linking chemotherapy order management with registry functionality, the company took an early step toward meeting the rising demand for digital precision in oncology and the need for standardized documentation in cancer care.
Following its initial adoption in the United States, Altai Oncology soon expanded its reach internationally. In 2016, Malaysia became one of the first countries outside the U.S. to implement the Altai Oncology Suite. This expansion reflected a broader global movement toward digital interoperability and the centralization of treatment databases across healthcare systems.
Altai’s oncology solutions have since entered multiple markets, gradually building a base of cancer centers, hematology departments, and infusion clinics. Beyond its desktop platform, the introduction of the Altai Oncology Mobile App—available on both Android and iOS—marked an important milestone. The mobile platform enabled oncologists to review chemotherapy protocols, perform calculations, and access staging modules from any location. These advancements aligned with the worldwide adoption of mobile health technologies and the increasing use of cloud-based clinical management systems.
In 2015, Altai established its curated Protocol Library, which now includes more than 1,000 chemotherapy and hematology treatment protocols. This database functions as a reference system that supports clinicians’ daily work while reflecting the most current clinical standards and drug guidelines. By embedding the library into both desktop and mobile systems, Altai reinforced the essential link between medical research and clinical execution.
Although headquartered in Sheridan, Wyoming, the company conducts most of its research and software development in Turkey through its subsidiary, Altay Tıp Sağlık Yazılım AŞ. This Turkish branch serves as the company’s primary R&D center and holds ISO 13485 certification, a key quality-management standard for medical device software. The certification highlights Altai’s adherence to internationally recognized requirements for the development and maintenance of medical-grade digital tools.
From its Ankara offices, the R&D team has played a central role in advancing Altai’s product architecture. The team has contributed to enhancements in dose-calculation algorithms, integration with hospital information systems, and improvements in user workflow design. Collaboration between the U.S. and Turkish teams has enabled the company to maintain CE marking for its software, classifying the Oncology Suite as a Class IIb device under the European Union’s Medical Device Regulations. This status places the platform among regulated medical technologies that must meet strict safety and performance benchmarks within the European healthcare market.
Altai Oncology continues to build on its dual presence in the United States and Turkey, with long-term plans aimed at broader international expansion. The company aims to extend its oncology software to additional healthcare systems across Europe, the Middle East, and Asia. Its strategy is supported by a regulatory foundation that includes ISO 13485 certification, CE marking, and a modular platform that adapts to a variety of clinical environments.
Future development plans include strengthening clinical decision-support systems and expanding cloud-based interoperability frameworks. These initiatives are intended to improve how oncology data is captured, analyzed, and shared across multidisciplinary teams. Altai has also indicated its intention to broaden the scope of its Oncology Suite and Chemo Planner platforms to support smaller private practices as well as large hospital networks.
Advances in artificial intelligence and predictive analytics are expected to influence the company’s future product capabilities. While Altai has not yet disclosed details about AI-powered features, the increasing use of algorithmic modeling in oncology suggests that future system updates may incorporate automated treatment suggestions, toxicity prediction tools, or other machine-assisted decision-support mechanisms. By aligning its platforms with the technologies shaping the future of cancer care, Altai is positioning itself to remain competitive within the oncology informatics sector.
Since 2013, Altai Oncology has grown from a small health information technology startup into a software provider with international distribution. Its development reflects how specialized oncology software can transform patient care and modernize the operational framework of cancer treatment centers. Through its combination of U.S.-based corporate leadership and Turkey-based research activities, Altai has established an innovation model that is both transcontinental and collaborative.
As oncology care increasingly relies on digital integration, companies like Altai are playing a crucial role in setting new standards for clinical efficiency, safety, and data management. The firm’s evolution mirrors the broader movement toward precision, structure, and cross-border collaboration in medicine, demonstrating how a focused local initiative can progress into a global contributor within the ever-advancing field of cancer care.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute medical advice. Altai Oncology’s products and services should be used in accordance with applicable regulations and under the supervision of qualified healthcare professionals. Always consult with a medical professional for personalized healthcare guidance.
